Myelofibrosis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Active Biotech, Hinova Pharmaceuticals, AbbVie, iOnctura, Sumitomo Pharma Oncology

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myelofibrosis pipeline constitutes 45+ key companies continuously working towards developing 45+ Myelofibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Myelofibrosis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myelofibrosis Market.

The Myelofibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Myelofibrosis Pipeline Report: https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Myelofibrosis treatment therapies with a considerable amount of success over the years.
• Myelofibrosis companies working in the treatment market are Active Biotech, Hinova Pharmaceuticals, AbbVie, iOnctura, Sumitomo Pharma Oncology, Pharmaxis, Keros Therapeutics, Nippon Shinyaku, Incyte Corporation, MorphoSys, Geron Corporation, and others, are developing therapies for the Myelofibrosis treatment
• Emerging Myelofibrosis therapies in the different phases of clinical trials are- Tasquinimod, HC-X027, ABBV-744, OA-244, TP-3654, PXS-5505, KER-050, NS-018, Parsaclisib, Pelabresib, Imetelstat, and others are expected to have a significant impact on the Myelofibrosis market in the coming years.
• In June 2022, Cellenkos revealed that its application for an Investigational New Drug (IND) to start an open-label, Phase Ib study of CK0804 as an adjuvant therapy for patients with myelofibrosis who do not respond well to ruxolitinib has been approved by the US Food and Drug Administration (FDA).
• In June 2022, Updated positive data from Imago Biosciences' ongoing worldwide Phase II clinical study assessing bomedemstat in patients with advanced myelofibrosis were presented. Bomedemstat was generally well-tolerated and safe in myelofibrosis patients.
• In June 2022, revealed that TP-3654, a patented experimental oral PIM kinase inhibitor developed by Sumitomo Pharma Oncology, has received Orphan Drug Designation by the US FDA to treat myelofibrosis.
• In June 2022, New results from Cohort 3 of AbbVie's Phase II REFINE trial, which examined the combination of ruxolitinib and experimental navitoclax in patients with myelofibrosis (MF), a rare and challenging blood malignancy to treat, who had not yet used a JAK inhibitor, was released. These findings supported the possibility of better clinical outcomes and the significance of early intervention in myelofibrosis.
• In February 2022, With Oncode Institute in the Netherlands, Active Biotech entered into an exclusive license agreement for the worldwide rights to patents pertaining to the use of tasquinimod and other S100 inhibitors for the treatment of myelofibrosis.

Myelofibrosis Overview
In the uncommon condition known as myelofibrosis, normal bone marrow tissue gradually gives way to a fibrous substance that resembles scar tissue.It is categorized as a form of chronic leukemia and is a member of the myeloproliferative diseases group of blood illnesses.

Get a Free Sample PDF Report to know more about Myelofibrosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Myelofibrosis Drugs Under Different Phases of Clinical Development Include:
• Tasquinimod: Active Biotech
• HC-X027: Hinova Pharmaceuticals
• ABBV-744: AbbVie
• OA-244: iOnctura
• TP-3654: Sumitomo Pharma Oncology
• PXS-5505: Pharmaxis
• KER-050: Keros Therapeutics
• NS-018: Nippon Shinyaku
• Parsaclisib: Incyte Corporation
• Pelabresib: MorphoSys
• Imetelstat: Geron Corporation

Myelofibrosis Route of Administration
Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Myelofibrosis Molecule Type
Myelofibrosis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Myelofibrosis Pipeline Therapeutics Assessment
• Myelofibrosis Assessment by Product Type
• Myelofibrosis By Stage and Product Type
• Myelofibrosis Assessment by Route of Administration
• Myelofibrosis By Stage and Route of Administration
• Myelofibrosis Assessment by Molecule Type
• Myelofibrosis by Stage and Molecule Type
DelveInsight's Myelofibrosis Report covers around 45+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Myelofibrosis product details are provided in the report. Download the Myelofibrosis pipeline report to learn more about the emerging Myelofibrosis therapies at:
https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Myelofibrosis Therapeutics Market include:
Key companies developing therapies for Myelofibrosis are - Incyte Corporation, Pfizer Inc., Amneal Pharmaceuticals, Inc., AbbVie Inc., Actuate Therapeutics Inc., CTI BioPharma Corp, Galecto, Inc., GlaxoSmithKline plc, Imago BioSciences, Bristol-Myers Squibb Company, and others.

Myelofibrosis Pipeline Analysis:
The Myelofibrosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Myelofibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelofibrosis Treatment.
• Myelofibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myelofibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelofibrosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myelofibrosis drugs and therapies-
https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Myelofibrosis Pipeline Market Drivers
• Increase in R&D for the development of new and effective drug for the treatment, increasing Incidence in Elderly Population, development of biological therapies or immunotherapies are some of the important factors that are fueling the Myelofibrosis Market.

Myelofibrosis Pipeline Market Barriers
• However, side effects associated with the drugs, high cost of therapy and other factors are creating obstacles in the Myelofibrosis Market growth.

Scope of Myelofibrosis Pipeline Drug Insight
• Coverage: Global
• Key Myelofibrosis Companies: Active Biotech, Hinova Pharmaceuticals, AbbVie, iOnctura, Sumitomo Pharma Oncology, Pharmaxis, Keros Therapeutics, Nippon Shinyaku, Incyte Corporation, MorphoSys, Geron Corporation, and others
• Key Myelofibrosis Therapies: Tasquinimod, HC-X027, ABBV-744, OA-244, TP-3654, PXS-5505, KER-050, NS-018, Parsaclisib, Pelabresib, Imetelstat, and others
• Myelofibrosis Therapeutic Assessment: Myelofibrosis current marketed and Myelofibrosis emerging therapies
• Myelofibrosis Market Dynamics: Myelofibrosis market drivers and Myelofibrosis market barriers

Request for Sample PDF Report for Myelofibrosis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Myelofibrosis Report Introduction
2. Myelofibrosis Executive Summary
3. Myelofibrosis Overview
4. Myelofibrosis- Analytical Perspective In-depth Commercial Assessment
5. Myelofibrosis Pipeline Therapeutics
6. Myelofibrosis Late Stage Products (Phase II/III)
7. Myelofibrosis Mid Stage Products (Phase II)
8. Myelofibrosis Early Stage Products (Phase I)
9. Myelofibrosis Preclinical Stage Products
10. Myelofibrosis Therapeutics Assessment
11. Myelofibrosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Myelofibrosis Key Companies
14. Myelofibrosis Key Products
15. Myelofibrosis Unmet Needs
16 . Myelofibrosis Market Drivers and Barriers
17. Myelofibrosis Future Perspectives and Conclusion
18. Myelofibrosis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Myelofibrosis Market https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Myelofibrosis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Myelofibrosis Epidemiology https://www.delveinsight.com/report-store/myelofibrosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Myelofibrosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.